

1 **Multi-ancestry Fine Mapping of Interferon Lambda and the Outcome of Acute Hepatitis C**
2 **Virus Infection**

3 Candelaria Vergara¹, Priya Duggal¹, Chloe L. Thio², Ana Valencia^{2,3}, Thomas R. O'Brien⁴,
4 Rachel Latanich², Winston Timp², Eric O. Johnson⁵, Alex H. Kral⁵, Alessandra Mangia⁶, James
5 J. Goedert⁷, Valeria Piazzola⁶, Shruti H. Mehta¹, Gregory D. Kirk¹, Marion G. Peters⁸, Sharyne
6 M. Donfield⁹, Brian R. Edlin¹⁰, Michael P. Busch¹¹, Graeme Alexander¹², Edward L. Murphy¹¹,
7 Arthur Y. Kim¹³, Georg M. Lauer¹⁴, Raymond T. Chung¹⁴, Matthew E. Cramp¹⁵, Andrea L.
8 Cox², Salim I. Khakoo¹⁶, Hugo R. Rosen¹⁷, Laurent Alric¹⁸, Sarah J. Wheelan^{1,2}, Genevieve L.
9 Wojcik¹⁹, David L. Thomas² and Margaret A. Taub¹.

10 ¹ Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD. USA.

11 ² Johns Hopkins University, School of Medicine, Baltimore, MD, USA

12 ³ Universidad Pontificia Bolivariana, Medellin, Colombia.

13 ⁴ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes
14 of Health, Bethesda, MD, USA

15 ⁵ RTI International, Research Triangle Park, NC. USA

16 ⁶ Liver Unit IRCCS "Casa Sollievo della Sofferenza", San Giovanni Rotondo, Italy

17 ⁷ Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes
18 of Health, Bethesda, MD. USA

19 ⁸ Department of Gastroenterology, University of California, San Francisco, CA., USA.

20 ⁹ Rho, Inc., Chapel Hill, NC, USA

21 ¹⁰ Centers for Disease Control and Prevention, Atlanta, GA., USA

22 ¹¹ University of California San Francisco and Vitalant Research Institute, San Francisco, CA.,
23 USA

24 ¹² University College London Institute for Liver and Digestive Health, The Royal Free Hospital,
25 London, UK.

26 ¹³ Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital and
27 Harvard Medical School, Boston, MA. USA

28 ¹⁴ Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General
29 Hospital and Harvard Medical School, Boston, MA.,USA

30 ¹⁵ South West Liver Unit, Plymouth, PL6 8DH, UK.

31 ¹⁶ University of Southampton, Southampton General Hospital, Southampton, UK.

32 ¹⁷ University of Colorado, Aurora, CO., USA

33 ¹⁸ Department of Internal Medicine and Digestive Diseases, Centre Hospitalier Universitaire
34 Rangueil, UMR 152, Institut de Recherche pour le Développement Toulouse 3 University,
35 France.

36 ¹⁹ Department of Genetics, Stanford University School of Medicine, Stanford, CA., USA

37 **Short title**

38 Fine-mapping of *IFNL* Locus for HCV clearance

39 **Corresponding Author**

40 Candelaria Vergara, MD, PhD

41 725 N. Wolfe Street, Suite 211

42 Baltimore, Maryland 21205

43 Email: cvergar2@jhmi.edu

44 **Disclosures:** All authors declare that they have no conflict of interest and nothing to disclose.

45

46 **Funding:** R01 013324, R01-HD-41224, R01-AI148049-21, R21AI139012, U19-AI082630,
47 U01-AI131314, R01-DA033541, U19-AI066345, DA12568, DA036297, R01-DA09532, R01-
48 DA11860, N02CP91027, H79TI12103, R01DA16159, R01DA21550, R01-HD-41224.

49 **Abstract:**

50 Clearance of acute infection with hepatitis C virus (HCV) is associated with the chr19q13.13
51 region containing the rs368234815 (TT/ Δ G) polymorphism. We fine-mapped this region to
52 detect possible causal variants that may contribute to HCV-clearance. First, we performed
53 sequencing of *IFNL1-IFNL4* region in 64 individuals sampled according to rs368234815
54 genotype: TT/clearance (N=16) and Δ G/persistent (N=15) (genotype-outcome concordant) or
55 TT/persistent (N=19) and Δ G/clearance (N=14) (discordant). 25 SNPs had a difference in
56 counts of alternative allele > 5 between clearance and persistence individuals. Then, we
57 evaluated those markers in an association analysis of HCV clearance conditioning on
58 rs368234815 in two groups of European (692 clearance/1 025 persistence) and African
59 ancestry (320 clearance/1 515 persistence) individuals. 10/25 variants were associated ($P <$
60 0.05) in the conditioned analysis led by rs4803221 ($P=4.9 \times 10^{-04}$) and rs8099917 ($P=5.5 \times 10^{-}$
61 04). In the European ancestry group, individuals with the haplotype rs368234815 Δ G/rs4803221C
62 were 1.7x more likely to clear than those with the rs368234815 Δ G/rs4803221G haplotype
63 ($P=3.6 \times 10^{-5}$). For another nearby SNP, the haplotype of rs368234815 Δ G/rs8099917T was
64 associated with HCV-clearance compared to rs368234815 Δ G/rs8099917G (OR: 1.6, $P=1.8 \times 10^{-}$
65 4). We identified four possible causal variants: rs368234815, rs12982533, rs10612351 and
66 rs4803221. Our results suggest a main signal of association represented by rs368234815, with
67 contributions from rs4803221, and/or nearby SNPs including rs8099917.

68 **Introduction**

69 The outcome of the acute hepatitis C virus (HCV) infection is determined in part by host genetic
70 factors. Previous genome-wide association studies (GWAS) and meta-analyses have identified
71 significant associations of spontaneous clearance of HCV infection with several single
72 nucleotide polymorphisms (SNPs) in the region harboring 4 interferon- λ genes (*IFNL1*, *IFNL2*,
73 *IFNL3* and *IFNL4*) on chromosome 19q13.13 (1-3). Of particular importance is a dinucleotide
74 variant in the first exon of *IFNL4*, rs368234815 (Δ G/TT), which causes a shift in the open
75 reading frame of the gene; the presence of the Δ G allele at the variant position allows the
76 expression of a fully functional IFN λ 4 protein of 179 amino-acids (4,5). This allele is
77 implicated in reduced HCV clearance (4). On the contrary, the TT allele is predicted to induce
78 nonsense-mediated mRNA decay and is associated with increased HCV clearance (4) (Figure
79 1, Top panel).

80 Despite the strong and replicated association, some HCV infected individuals carrying the
81 favorable genotype (TT) of rs368234815 do not clear the infection, while some patients with the
82 unfavorable genotypes spontaneously clear the infection (4,6-10). This discordant *IFNL*
83 genotype with HCV infection outcomes are not explained by other determinants of
84 spontaneous clearance such as polymorphisms in other known HCV related genes, sex, or
85 HIV co-infection. Thus, we reasoned that other variants in the *IFNL* region may contribute to
86 the observed spontaneous clearance.

87

88 The *IFNL1-IFNL4* region is under strong linkage disequilibrium (LD) which complicates the
89 identification of causal alleles (11). Moreover, sequencing of the region is limited by the
90 presence of genes with high homology that precludes the accurate assignment of reads to a
91 specific location (12,13). In this study we sought to overcome these challenges and to identify

92 variants that may contribute to clearance of HCV infection. We implemented two approaches to
93 identify variants with an association independent of rs368234815 (Figure 2). First, we
94 performed short-read sequencing analysis in a selected panel of individuals where the
95 rs368234815 genotype was either concordant or discordant with the expected HCV outcome
96 (clearance or persistence) using a sequencing strategy that allowed the precise assignment of the
97 reads to specific coordinates in the locus and accurate calling of the variants. Second, we
98 performed conditional analysis in a large independent set of individuals of European and
99 African ancestry evaluated for display of HCV spontaneous clearance for whom we had
100 genotypes imputed to the 1000 Genomes Project (14). To identify potential causal variants in the
101 region we used well established statistical methods combining functional data from external
102 sources with the association and LD patterns from our datasets (Figure 2). We also interrogated
103 our dataset for association of two variants (rs1176648444 and rs4803217) that have been
104 identified as functionally relevant in the region.

105 **Materials and Methods**

106 **Genetic structure of the *IFNL* region:** The interferon lambda region spans 50Kb of human
107 chromosome 19q (15,16), Figure 3. The 4 interferon- λ genes seem to originate from gene
108 duplication events (4,17) with *IFNL2* and *IFNL3* more closely related to each other than *IFNL1*
109 (4). *IFNL1* and *IFNL2* are transcribed from the positive strand with a coding region of 2,348 and
110 1,445 basepairs (bp), with 5 and 6 exons, respectively. *IFNL3* and *IFNL4* have 6 and 5 exons
111 each, are transcribed from the negative strand and have a coding region of 1 336 and 2 543 bp,
112 respectively (Figure 3) (16).

113 ***Short-read sequencing in panel of discordant and concordant individuals***

114 Individuals for IFNL Sequencing: Individuals included in this approach are part of the HCV
115 Extended Genetics Consortium (2,18). Each individual study obtained consent for genetic testing
116 from their governing Institutional Review Board and the overall research was approved by the
117 Johns Hopkins School of Medicine Institutional Review Board (3). For this analysis we selected
118 64 individuals based on the genotype of rs368234815 and HCV spontaneous
119 clearance/persistence status in a similar approach presented by Rauch et al for rs8099917 (1).
120 This included 45 individuals of African Ancestry (21 clearance/24 persistence) and 19
121 individuals of European Ancestry (9 clearance/10 persistence) (Table 1, Figure 1, Bottom panel).
122 These individuals were either concordant between genotype and HCV outcome (i.e. favorable
123 genotype of rs368234815 [TT/TT] and HCV spontaneous clearance or unfavorable genotypes
124 rs368234815 [Δ G/ Δ G] and HCV persistence) or were discordant (i.e. favorable genotype and
125 HCV persistence or unfavorable genotype and HCV clearance) (Table 1, Figure 1, Bottom
126 panel).

127 IFNL Sequencing: Because the region containing the four *IFNL* genes has low sequence
128 complexity, the alignment of short reads generated with standard high-throughput sequencing
129 methods is challenging (12); thus, we designed a targeted sequencing approach where the entire
130 70.8 Kb region (chromosome 19:39721399-39792284, coordinates based on The Genome
131 Reference Consortium Human build 37-GRCh37-) was amplified in eight segments with
132 customized primers (Figure 3, Supplementary Table 1). This allowed alignment of reads
133 specifically to the region of origin, resulting in more confident detection of individual variants
134 across the whole region. Methods of DNA extraction and strategies for sequencing and
135 alignment are described in detail in Supplementary Material.

136 Statistical Analysis of the sequenced panel: Counts of alternative (non-reference, non-ancestral)
137 alleles at each position of the sequenced region were generated to compare differences in single-
138 nucleotide variants (SNVs) between concordant and discordant individuals. We report all
139 positions where the difference in alternative allele count is at least 5. Given sample size
140 limitations, we did not perform formal statistical tests for differences between groups, but report
141 all positions for validation in imputation data. Customized scripts in R ([https://www.r-](https://www.r-project.org/)
142 [project.org/](https://www.r-project.org/)) were used to do the SNV analysis. Results of comparison of all variants included in
143 the analysis of the region is available upon request.

144 ***Conditional Analysis of an independent imputed dataset.***

145 Individuals of the independent imputed dataset: We analyzed the rest of the individuals of the
146 HCV Extended Genetics Consortium (2,18), corresponding to an independent set of 1835
147 individuals of African Ancestry (320 clearance/1515 persistence) and 1717 individuals of
148 European ancestry (692 clearance/1025 persistence). The rs368234815 Δ G allele had a
149 frequency of 0.63 in the African ancestry group and 0.31 in the European ancestry group
150 (Table 1).

151 Genotyping and Imputation: Genotypes in this region were derived from a genome-wide
152 association study previously described (2,3) and in Supplementary Material. For this analysis,
153 421 high quality imputed variants in the *IFNL* region were used in African ancestry individuals
154 and 282 in European ancestry individuals.

155 Statistical Analysis of the independent imputed dataset: In each of the ancestry groups, we
156 performed an association analysis of dosage of the variants in the region conditioned on the
157 rs368234815 variant using an additive logistic regression model, adjusting for 3 principal

158 components and HIV status using Mach2dat (19). Conditional analysis in the two ancestry
159 groups were meta-analyzed using the fixed effects inverse variance method in METAL software
160 (20). Given that this region has been highly replicated and to preserve power for detect
161 secondary signals in the fine mapping, a value of $P < 0.05$ was considered as significant (21).
162 Results from the imputation analysis were pulled to check for significance at any of the loci that
163 were identified based on alternative allele counts from the sequencing analysis. Candidate sites
164 with difference in the allele count and significance in the imputed dataset were carried forward
165 for the haplotype analysis.

166 Haplotype analysis: To further characterize the locus across populations, we conducted
167 haplotype association analyses. We calculated LD and constructed haplotypes based on the
168 candidate sites in the European ancestry and African ancestry populations. LD patterns in each
169 population were calculated using the algorithm from Gabriel et al (22) in Haploview (23) in the
170 imputed dataset. We performed haplotype analyses using the “haplo.stat” R package (24). We
171 assumed an additive model in which the regression coefficient represented the expected change
172 in the log odds of HCV clearance with each additional copy of the specific haplotype compared
173 with the reference haplotype.

174 **Identification of potential causal variants**

175 To identify variants that may be causal or have a regulatory function we refined the region
176 observed in a previous GWAS of HCV clearance (3). We used association summary statistics
177 from GWAS for those markers in the *IFNL* region, leveraged functional data and LD
178 information of the included markers and described a 99% credible set of variants using
179 PAINTOR (25,26) as described in detail in Supplementary Materials. Aiming to optimize power
180 for this analysis, we included the complete dataset of the HCV Extended Genetic consortium

181 comprising 3608 people from two ancestry groups: 1869 individuals of African ancestry (340
182 clearance/1529 persistence) and 1736 of European ancestry (701 clearance/1,035 persistence).
183 We considered PAINTOR predicted variants to be functional based on a posterior probability >
184 0.1, a threshold suggested previously (26). To investigate functional elements, the presence or
185 absence of overlap was determined by the UCSC Table Browser intersecting the calculated
186 credible set with the signal tracks described in Supplementary Materials.

187 **Analysis of functionally relevant variants**

188 Two markers (Rs4803217 and Rs1176648444) has been described as modulators of the
189 association given by rs368234815 (Supplementary Material). Given their potential functional
190 role, we evaluated their allele count in the sequenced dataset and the association of each variant
191 in the imputed dataset after conditioning on rs368234815. We also evaluated the residual
192 association after conditioning on both rs368234815 and rs1176648444 and the association of the
193 rs368234815- rs4803217 and rs368234815- rs1176648444 haplotypes in each population and
194 using the methods described in haplotype analysis, we constructed and evaluated association of
195 haplotypes based on the candidate sites common to European and African ancestry populations
196 incorporating these functionally relevant variants.

197 **Results**

198 When analyzing all individuals of the sequencing group (concordants and discordants), we
199 identified 25 positions (candidate SNVs) where the difference in the frequency of the alternative
200 allele was >5 between the individuals with clearance and persistence (Table 2). The identified
201 variants are located downstream of *IFNL3-IFNL4* and in the intergenic regions between *IFNL4-*
202 *IFNL2* and *IFNL2-IFNL1* (Supplementary Figure 1).

203 Conditional Analysis in an independent imputed dataset. From all the variants analyzed in the
204 region in this dataset, we extracted the results of the 25 variants identified in the targeted
205 sequencing panel. From those, 2 variants were not present in both ancestry groups and 10
206 candidate variants were significantly associated (P value < 0.05) in the meta-analysis
207 (Supplementary Figure 1, Table 2). No other variants in the region was significantly associated
208 in the conditional analysis.

209 The 10 candidate variants are located in an 11.3Kb region (chr19: 39732501-39743821)
210 spanning 1.7 Kb downstream of *IFNL3* and 4.3Kb upstream of *IFNL4* (Figure 4, Panel A-B and
211 Supplementary Figure 1). The association observed in this meta-analysis was driven mainly by
212 the contribution of the European ancestry samples (Table 2). In this group, nine of ten associated
213 variants have similar minor allele frequencies (~ 0.19) with the exception being rs4803222
214 (0.30). Rs4803221, a synonymous SNP in *IFNL4* (NM_001276254: S (TCG) --> S (TCC)), had
215 the strongest association in the meta-analysis (P-value = 4.86×10^{-04}) and in the European
216 ancestry group (P-value = 7.49×10^{-06}). In the African ancestry population, the direction of the
217 effect is the same but no variants were significantly associated. The allele frequencies for seven
218 of ten variants were similar across the ancestry groups. However, at rs8107030, rs8099917 and
219 rs7248668 minor allele frequencies were lower in the African ancestry population (0.04-0.06)
220 than in persons of European ancestry (0.19) (Table 2).

221 Haplotype analysis. The markers included in the haplotype analysis were rs368234815 and the
222 ten candidate variants (Figure 4, Panel C). Haplotype construction revealed that in the European
223 ancestry individuals all 11 SNPs are within one unique haplotype block of 11kb with LD values
224 consistently high ($r^2 > 0.89$), except for rs4803222 and rs368234815 with an $r^2 \sim 0.50$ with the

225 other variants (Figure 4). Thus, the top SNP of the candidate variants (rs4803221) tags all
226 associated variants in the block except for rs4803222 and rs368234815.

227 We estimated the frequency of the haplotypes based on the boundaries determined in the
228 haplotype blocks for each population. In the European ancestry samples, the 11 markers formed
229 24 haplotypes of which four (denoted H1 to H4) had a frequency higher than 2 % so were
230 included in the haplotype association analysis (Supplementary Table 2). H1 (containing the
231 favorable TT allele of rs368234815) was the haplotype with highest prevalence overall and was
232 more frequent in the clearance group (P-value= 4.4×10^{-22}). H2, H3 and H4 contained the
233 unfavorable allele (ΔG) of rs368234815. H3 and H4 and were significantly associated with
234 persistence (P value < 0.05. H2 had a low prevalence (2%) and was not associated with HCV
235 clearance (P value = 0.53).

236 In African ancestry individuals, there was unique haplotype block of 5Kb containing 9 out of the
237 11 variants with LD r^2 values ranging from 0.99 to 0.03 (Figure 4). In this population rs4803221
238 is able to capture information only from rs8105790, rs66531907, rs12983038, rs8109889 but not
239 from rs8099917 or rs7248668. Similarly, rs8107030, rs368234815 and rs4803222 only capture
240 information from themselves. Similar to the European ancestry population, rs368234815 had low
241 LD r^2 values with the ten variants (Figure 4).

242 In African ancestry individuals, 21 haplotypes were present and five with the highest frequency
243 (> 6%) were included in the analysis. Haplotypes H1-H4 are similar to those of the European
244 ancestry populations for the shared markers. Similarly, H1 was more frequent in the clearance
245 group (P value= 1.5×10^{-14}), however, this haplotype had a considerably lower prevalence in this

246 sample compared to the European ancestry sample (37.5% vs. 68.1%), which can be explained
247 by the differences in the allelic frequency of the ΔG allele between those samples (Table 1).

248 In the African ancestry sample, H2 was the predominant haplotype conferring persistence and
249 has a considerably higher prevalence in this African ancestry group (36% vs 2% in the European
250 group). H3 and H4 were associated with persistence with comparable effect size but lower
251 significance ($P = 0.02$). In summary, in both sample groups H1 was significantly associated with
252 clearance. However, the predominant haplotypes conferring persistence were different in each
253 sample group (H3 in European ancestry vs. H2 in African ancestry individuals), Supplementary
254 Table 2. Similar results were observed in the haplotype analysis including common candidate
255 variants and functionally relevant variants, except for the separation of H2 in African Ancestry
256 individuals in H2a and H2b. H2b conserved similar direction and strength of effect than H2
257 (Supplementary Table 3) .

258 Next, to determine whether an allele or haplotype could “overcome” the unfavorable allele (ΔG)
259 of rs368234815, we restricted our analysis to haplotypes containing this unfavorable allele in the
260 European ancestry group. We found that the haplotypes with the C allele at rs4803221 were
261 significantly associated with clearance compared to those containing the G allele (OR: 1.7, 95%
262 CI: 1.3-2.29, P value = 3.6×10^{-5} , Table 3). This was not observed in African ancestry
263 individuals (OR for haplotype with the C allele: 1.25; 95% CI: 0.81-1.9, P value = 0.29).
264 Rs4803221 tags rs8099917 and rs7248668 in the European ancestry group but not in the African
265 ancestry group. Similar to rs4803221, the haplotype containing the T allele of rs8099917 (and G
266 allele of rs7248668) is significantly associated with clearance compared to the one containing the
267 G allele of rs8099917 (and A allele of rs7248668: OR: 1.6, 95% CI: 1.3-2.16, P value: 1.76×10^{-4})
268 4) in the European ancestry individuals but not in African ancestry individuals (Table 3). These

269 data are consistent with a main signal being shared across populations driven by one or more
270 functional variants represented by rs368234815, with potential additional contributions from
271 rs4803221, and/or proxies including rs8099917 and rs7248668 in the European ancestry
272 population.

273 **Identification of potential causal variants**

274 Four SNPs were identified as likely functional (posterior probability > 0.1, Supplementary Table
275 4). The credible set obtained with PAINTOR, determined by 2 out of 4 variants of the credible
276 set (rs368234815 and rs12982533), overlaps with the previously estimated credible set using a
277 larger dataset (3), narrowing the signal to a 7251 bp region (19:39731904-39739155) located
278 2368bp downstream from *IFNL3* and extending until exon 1 of *IFNL4* (Supplementary Figure 2).
279 The identified region includes rs368234815 which we confirmed as the main driver of the
280 association signal. The variants identified in the fine-mapping credible set overlapped with
281 regulatory regions in hepatocyte cell lines and liver tissue including CpG sites that are
282 completely or partially methylated, target sites for transcription factors, DNA methylation sites
283 with 50-100% methylation in those cells, candidate weak enhancers, polycomb repressors and
284 with transcription associated activity (Supplementary Figure 2). Two other variants (rs4803221
285 and rs10612351) also showed posterior probability values > 0.10 indicating that they might be
286 considered causal even though rs10612351 is not included in calculated 99% credible set. We
287 considered that these polymorphisms are plausible candidate variants based both on fine-
288 mapping and regulatory overlap and these results support the findings of the haplotype analysis.

289 **Analysis of functionally relevant variants**

290 Rs4803217 and rs1176648444 had a difference of 1 and 0 respectively in the counts of the
291 alternative allele between clearance and persistence in the sequenced panel. Rs4803217 showed
292 no association in the imputed dataset after conditioned on rs368234815 (European ancestry
293 conditioned P value= 0.15, African ancestry conditioned P value= 0.3, Meta-analysis conditioned
294 P value= 0.08). Rs1176648444 was not associated in African Ancestry (P value= 0.38) but
295 interestingly it showed a significant association in individuals of European Ancestry only in the
296 conditioned analysis (Not conditioned P value= 0.07; conditioned P value=0.00003, conditioned
297 meta-analysis P value = 0.06). In the double conditioned analysis with rs368234815 and
298 rs1176648444, six out of ten variants associated in the single conditioned analysis showed
299 residual association (Supplementary Table 5). Rs368234815TT- Rs4803217C haplotype was
300 significantly associated with clearance compared with the Rs368234815ΔG-Rs4803217A in both
301 populations. In African ancestry population the haplotype Rs368234815ΔG-Rs4803217C was
302 significantly associated with persistence (Supplementary Table 6). On the other hand, in the
303 European ancestry population, the haplotype rs368234815ΔG- rs1176648444A (IFNλ4-S70) was
304 associated with clearance with an intermediate effect between rs368234815ΔG-rs1176648444G
305 (IFNλ4-P70) and rs368234815TT-rs1176648444G (no IFNλ4), Supplementary Table 7.

306 **Discussion**

307 We performed a comprehensive, trans-ethnic analysis of genetic variation in the *IFNL* region and
308 spontaneous recovery from HCV infection. We discovered variants with associations
309 independent of the well-described rs368234815 variant that suggest additional genetic
310 contributions to the outcome of this chronic infection.

311 We observed an rs368234815-independent signal led by rs4803221 (given mainly for the
312 European Ancestry population) and ten other variants in LD including rs8099917 and rs7248668.

313 In sensitivity analysis we confirmed that this signal was present even after conditioning on
314 rs368234815 and rs1176648444 indicating a residual or modifying effect of the remaining variants. The
315 LD structure of the region in the European ancestry group suggests that the rs4803221
316 association may be due to any one of a number of variants including rs8099917 and rs7248668.
317 In fact, in the context of haplotypes conferring persistence in this group, the haplotype containing
318 the C allele of rs4803221, the T allele of rs8099917 and the G allele of rs7248668 were
319 significantly associated with HCV clearance. However, we do not observe a significant signal in
320 individuals of African ancestry at rs4803221, even though its allele frequency and the sample
321 size are similar to the European ancestry group. It is possible that the association of rs4803221
322 observed in the European ancestry group is explained by linkage with rs8099917 and/or
323 rs7248668, instead of being functional itself. Unfortunately, our power was limited to confirm
324 this inference in the African ancestry group, where we detected an odds ratio of 0.79 with a MAF
325 of 0.06 (power of only 0.38 at a significance level of 0.05, compared to 1 in the European
326 ancestry group) (27).

327 Rs4803221 is a variant with multiple functions which has been previously linked to HCV
328 spontaneous clearance in individuals with beta thalassemia (28). The SNP is located in exon one
329 of *IFNL4*, 357 bp downstream from the transcription start site and 3522 bp upstream from the
330 transcription start site of *IFNL3*; the G allele (MAF=0.2) abolishes a CpG site and induces a
331 synonymous (Ser>Ser) change at position 30 of the *IFNL4* protein. Similar to our findings, Origa
332 *et al*, found an association with rs4803221 that was independent of rs12979860 (which is itself in
333 high LD with rs368234815) (28) . Rs4803221 significantly improved the viral clearance
334 prediction in patients carrying the un-favorable T allele of rs12979860 (in high LD with the un-
335 favorable Δ G allele of rs368234815). They hypothesized that the abolishment of methylation

336 sites might increase expression of *IFNL3* and downregulate interferon sensitive genes, reducing
337 net innate antiviral activity (28).

338 A potential ‘causal’ role has also been described for rs8099917 (1). In a GWAS including 1362
339 European ancestry individuals, G allele was associated with persistence of HCV infection (1).
340 Several specific SNPs were identified as candidates for being causal, however rs368234815 was
341 not described in this panel. In European HCV-infected individuals analyzed for response
342 treatment, haplotypes tagged by the T allele of rs8099917 showed higher expression of IFN λ 3
343 and IFN λ 2 but no evaluation was reported on expression of IFN λ 4 (29). Analogous results were
344 found in a Japanese cohort where the expression *IFNL3* and *IFNL2* mRNA was lower in the
345 carriers of the G allele (30). In our current study, T allele is associated with clearance in the
346 context of the Δ G allele of rs368234815, which corresponds with *IFNL4* transcription but HCV
347 persistence (4). Rs8099917 is located 8.9 kb upstream from *IFNL3* and 16 kb upstream from
348 *IFNL2*. If we assume the model that rs368234815 regulates the expression of IFN λ 4 (Figure 1),
349 it would be worthwhile to investigate if the statistically independent effect of rs8099917
350 observed in this study is perhaps caused by an increase in expression of IFN λ 3 and IFN λ 2, a
351 decrease in the production of IFN λ 4 in those individuals with the Δ G allele at rs368234815, or
352 both.

353 SNP rs7248668 located in the 5’ region of *IFNL4* is in high LD with rs8099917 in populations
354 included in this analysis and in The 1000 Genomes Project independently of ancestry (14). In
355 fine mapping analysis, the haplotype containing the G allele was associated with virologic
356 response to pegylated interferon- α and ribavirin therapy for chronic hepatitis C in a Japanese
357 population (30). Similarly, the patients with the GG genotype showed virologic response rates up
358 to four times higher than those for patients with unfavorable genotypes in HIV/HCV co-infected

359 patients of European ancestry (31). In our study the same G allele is associated with spontaneous
360 clearance; even though the phenotypes are not completely comparable, in general the G allele
361 favors the clearance of the virus in each context across studies. Due to their high LD the effect of
362 rs7248668 is not separable from that of rs8099917.

363 Our fine mapping analysis using PAINTOR indicates that the potential causal variant in this
364 locus is contained in the *IFNL3-IFNL4* gene region. This credible set informed by our analysis
365 harbors the compound di-nucleotide exonic variant (rs368234815, ΔG/TT) and the rs4803221
366 variant, but does not contain rs8099917 or rs7248668. It is possible that we did not find a high
367 posterior probability for those 2 latter SNPs because they are in high LD with rs4803221 in
368 European ancestry subjects, where the significant independent effect was observed. We consider
369 that the expansion of the sample size of African ancestry individuals could allow
370 disentanglement of the effects of rs4803221, rs8099917 and rs7248668. The coding nature of the
371 rs368234815, the high significance and large effect-size, and the low LD between this variant
372 and the others in the region (especially in the African ancestry population) contributed to
373 determine this variant as functionally relevant.

374 The identification of rs12982533 as functionally relevant deserves further analysis. This variant
375 has been included as part of haplotypes associated with response to treatment (13,32) but not
376 with spontaneous HCV clearance; it is located 3.7kb 3' of *IFNL3* and its functional role is
377 unknown. It is important to notice that we limited this analysis to only variants that were
378 consistently present in both ancestry groups and it is possible that this set of variants fails to
379 capture putatively important variation within or around the *IFNL* locus.

380 The results of the of rs368234815-rs1176648444 haplotype analysis in European ancestry agree
381 with findings previously described by the Swiss Hepatitis Cohort Study Group (33) where they
382 demonstrated that individuals with IFN λ 4-S70 have rates of HCV clearance that are
383 intermediate to those with IFN λ 4-P70 and those with rs368234815TT/TT genotype, who do not
384 produce the IFN λ 4 protein. Similarly, our findings on rs368234815-rs4803217 haplotype are in
385 concordance with the association of rs368234815 Δ G: rs4803217G with the poorest virologic
386 response to peg– interferon alpha and ribavirin therapy in African Americans (34); even though
387 it is not the same phenotype, it suggests an interaction of the two variants responsible for lower
388 rate of resolution of the infection in general. The restriction of the haplotype effect to specific
389 populations deserves further analysis including a larger sample capable of capturing all
390 haplotype diversity.

391 One strength of this analysis is the sequencing strategy which allowed us to unambiguously map
392 read pairs to specific segments of the *IFNL* region, and call the genetic variants with higher
393 accuracy than using conventional methods of short-read sequencing. The “conditioned by
394 design” composition of the panel with concordant and discordant individuals enabled the
395 detection of variants conferring an effect on HCV clearance that is adjusted for the allele present
396 at rs368234815. Even though the sample size of the sequencing panel is small, its particular
397 configuration makes it suitable to detect variants with a large effect. The findings from this panel
398 were supported by the results of the statistically conditioned analysis in a much larger sample
399 size with similar characteristics adding reliability to the findings. One limitation of the study is
400 that we established a rather high cut off for the selection of the variants with differences in the
401 allele count since the size of the panel precluded the evaluation of rare variants using standard

402 statistical tests and we excluded rare variants in the imputation panel since the imputation quality
403 is usually low for those variants and any derived results would be considered uncertain.

404 In this study we fine-mapped the *IFNL* region and found results that support an independent
405 genetic effect of several variants in this locus. Our results are applicable to the European ancestry
406 population with our current sample sizes and are hypothesis-generating regarding additional
407 factors contributing to the higher clearance in European ancestry and African ancestry
408 individuals. Our findings are relevant and complementary to previous analyses aimed to
409 understand the genetic basis of HCV clearance and the differences in the immune response to
410 this infection across populations.

411 **References**

412 (1) Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in
413 IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association
414 study. *Gastroenterology* 2010 Apr;138(4):1338-45, 1345.e1-7.

415 (2) Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, et al. Genome-wide
416 association study of spontaneous resolution of hepatitis C virus infection: data from multiple
417 cohorts. *Ann Intern Med* 2013 Feb 19;158(4):235-245.

418 (3) Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, et al. Multi-Ancestry
419 Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
420 *Gastroenterology* 2018 Dec 26.

- 421 (4) Prokunina-Olsson L, Muchmore B, Tang W, Pfeiffer RM, Park H, Dickensheets H, et al. A
422 variant upstream of IFNL3 (IL28B) creating a new interferon gene *IFNL4* is associated with
423 impaired clearance of hepatitis C virus. *Nat Genet* 2013 Feb;45(2):164-171.
- 424 (5) Hong M, Schwerk J, Lim C, Kell A, Jarret A, Pangallo J, et al. Interferon lambda 4
425 expression is suppressed by the host during viral infection. *J Exp Med* 2016 Nov
426 14;213(12):2539-2552.
- 427 (6) Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B
428 and spontaneous clearance of hepatitis C virus. *Nature* 2009 Oct 8;461(7265):798-801.
- 429 (7) Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A
430 polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus
431 and jaundice. *Gastroenterology* 2010 Nov;139(5):1586-92, 1592.e1.
- 432 (8) Knapp S, Warshow U, Ho KM, Hegazy D, Little AM, Fowell A, et al. A polymorphism in
433 IL28B distinguishes exposed, uninfected individuals from spontaneous resolvers of HCV
434 infection. *Gastroenterology* 2011 Jul;141(1):320-5, 325.e1-2.
- 435 (9) Aka PV, Kuniholm MH, Pfeiffer RM, Wang AS, Tang W, Chen S, et al. Association of the
436 IFNL4-DeltaG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus. *J Infect Dis*
437 2014 Feb 1;209(3):350-354.
- 438 (10) Chinnaswamy S. Genetic variants at the IFNL3 locus and their association with hepatitis C
439 virus infections reveal novel insights into host-virus interactions. *J Interferon Cytokine Res* 2014
440 Jul;34(7):479-497.

- 441 (11) Spain SL, Barrett JC. Strategies for fine-mapping complex traits. *Hum Mol Genet* 2015 Oct
442 15;24(R1):R111-9.
- 443 (12) Mandelker D, Schmidt RJ, Ankala A, McDonald Gibson K, Bowser M, Sharma H, et al.
444 Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical
445 next-generation sequencing. *Genet Med* 2016 Dec;18(12):1282-1289.
- 446 (13) Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, et al. Identification of
447 improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C
448 using massively parallel sequencing in a cross-sectional European cohort. *Genome Med* 2011
449 Aug 31;3(8):57.
- 450 (14) Sudmant PH, Rausch T, Gardner EJ, Handsaker RE, Abyzov A, Huddleston J, et al. An
451 integrated map of structural variation in 2,504 human genomes. *Nature* 2015 Oct
452 1;526(7571):75-81.
- 453 (15) Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-
454 lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. *Nat*
455 *Immunol* 2003 Jan;4(1):69-77.
- 456 (16) Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-
457 28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol* 2003 Jan;4(1):63-68.
- 458 (17) O'Brien TR, Prokunina-Olsson L, Donnelly RP. IFN-lambda4: the paradoxical new member
459 of the interferon lambda family. *J Interferon Cytokine Res* 2014 Nov;34(11):829-838.

- 460 (18) Wojcik GL, Thio CL, Kao WH, Latanich R, Goedert JJ, Mehta SH, et al. Admixture
461 analysis of spontaneous hepatitis C virus clearance in individuals of African descent. *Genes*
462 *Immun* 2014 Apr;15(4):241-246.
- 463 (19) Li Y, Willer C, Sanna S, Abecasis G. Genotype imputation. *Annu Rev Genomics Hum*
464 *Genet* 2009;10:387-406.
- 465 (20) Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide
466 association scans. *Bioinformatics* 2010 Sep 1;26(17):2190-2191.
- 467 (21) Schaid DJ, Chen W, Larson NB. From genome-wide associations to candidate causal
468 variants by statistical fine-mapping. *Nat Rev Genet* 2018 Aug;19(8):491-504.
- 469 (22) Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure
470 of haplotype blocks in the human genome. *Science* 2002 Jun 21;296(5576):2225-2229.
- 471 (23) Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and
472 haplotype maps. *Bioinformatics* 2005 Jan 15;21(2):263-265.
- 473 (24) Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association
474 between traits and haplotypes when linkage phase is ambiguous. *Am J Hum Genet* 2002
475 Feb;70(2):425-434.
- 476 (25) Kichaev G, Pasaniuc B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-
477 Mapping Studies. *Am J Hum Genet* 2015 Aug 6;97(2):260-271.

- 478 (26) Kichaev G, Yang WY, Lindstrom S, Hormozdiari F, Eskin E, Price AL, et al. Integrating
479 functional data to prioritize causal variants in statistical fine-mapping studies. PLoS Genet 2014
480 Oct 30;10(10):e1004722.
- 481 (27) Purcell S, Cherny SS, Sham PC. Genetic Power Calculator: design of linkage and
482 association genetic mapping studies of complex traits. Bioinformatics 2003 Jan;19(1):149-150.
- 483 (28) Origa R, Marceddu G, Danjou F, Perseu L, Satta S, Demartis FR, et al. IFNL3
484 polymorphisms and HCV infection in patients with beta thalassemia. Ann Hepatol 2015 May-
485 Jun;14(3):389-395.
- 486 (29) Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is
487 associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet
488 2009 Oct;41(10):1100-1104.
- 489 (30) Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-
490 wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for
491 chronic hepatitis C. Nat Genet 2009 Oct;41(10):1105-1109.
- 492 (31) Fernandez-Rodriguez A, Rallon N, Berenguer J, Jimenez-Sousa MA, Cosin J, Guzman-
493 Fulgencio M, et al. Analysis of IL28B alleles with virologic response patterns and plasma
494 cytokine levels in HIV/HCV-coinfected patients. AIDS 2013 Jan 14;27(2):163-173.
- 495 (32) Booth DR, Ahlenstiel G, George J. Pharmacogenomics of hepatitis C infections:
496 personalizing therapy. Genome Med 2012 Dec 26;4(12):99.

497 (33) Terczynska-Dyla E, Bibert S, Duong FH, Krol I, Jorgensen S, Collinet E, et al. Reduced
498 IFNlambda4 activity is associated with improved HCV clearance and reduced expression of
499 interferon-stimulated genes. Nat Commun 2014 Dec 23;5:5699.

500 (34) O'Brien TR, Pfeiffer RM, Paquin A, Lang Kuhs KA, Chen S, Bonkovsky HL, et al.
501 Comparison of functional variants in IFNL4 and λ L3 for association with HCV clearance. J
502 Hepatol 2015 Nov;63(5):1103-1110.

503

504 **Acknowledgments:** We thank the participants of the study. We also thank Cristian Velarde for
505 graphic design of the Figures.

506 **Legends of Tables**

507 **Table 1.** Genetic ancestry, HCV status and rs368234815 genotype distribution of the analyzed
508 individuals.

509 **Table 2.** Variants with a difference ≥ 5 in alternative allele count in sequenced individuals and
510 replication in the meta-analysis of the association test of imputed variants in the *IFNL* region
511 conditioned on the rs368234815 genotype. Bold text indicates positions with meta-analysis
512 $p < 0.05$ from imputed data.

513 **Table 3.** Association analysis of the 2 variant haplotypes (rs4803221-rs368234815 and
514 rs368234815- rs8099917) in individuals carrying the Δ G allele of rs368234815.

515 **Legends of Figures**

516 **Figure 1.** Top panel: Depiction of putative role of rs368234815 genotypes in HCV persistence or
517 clearance. Bottom panel: Schematic representation of concordant and discordant panels of
518 individuals used in the sequencing analysis.

519 **Figure 2.** Schematic representation of the fine mapping analysis performed in this study.

520 **Figure 3.** Genetic structure of the *IFNL* locus, amplified fragments used for targeted sequencing,
521 and two main variants associated in prior GWAS studies with HCV clearance (rs12979860 and
522 rs368234815). Genetic coordinates are based on The Genome Reference Consortium Human
523 build 37 (GRCh37/hg19).


524 **Figure 4.** Results of the analysis conditioned on rs368234815 and LD patterns of the top
525 associated variants from that analysis. A) Meta-analysis conditioned on rs368234815 genotype.
526 Variants represented in squares in panel B are the 23 of 25 variants that showed a difference of at
527 least 5 in counts between clearance and persistence groups in the sequencing analysis.
528 Recombination in this region is plotted in the background in light blue. Pairwise LD between the
529 top associated variant and other variants in the region were estimated using LD data in the
530 European (EUR) population in the 1000 Genomes project (hg19/Nov 2014). The color from blue
531 to red represents the r^2 values relative to the peak position after conditioning, rs4803221. B) P
532 values of rs368234815 and the 10 SNPs with remaining significance in the conditional analysis
533 and their location on the genes in the region. C) LD plot of those variants in individuals of
534 European and African ancestry in the genotyped/imputed dataset. The value within each
535 diamond of the LD plot represents the pairwise correlation between tagging SNPs defined by
536 sides of each the diamond. Shading represents the magnitude and significance of pairwise LD
537 represented by the r^2 value, with a red- yellow gradient reflecting higher to lower LD values.

538 Association plots were graphed with Locus Zoom, P value and LD plots were generated using
539 the package `snp.plotter` implemented in R.


Ancestry group	HCV status	Sequencing analysis (N=64)			Imputation analysis (N=3552)			
		Genotype at rs368234815 (n)		Total	Genotype at rs368234815 (n)			Total
		$\Delta G/\Delta G$	TT/TT		$\Delta G/\Delta G$	TT/ ΔG	TT/TT	
African Ancestry	Clearance	13	8	21	91	137	92	320
	Persistence	13	11	24	626	742	147	1515
	Total	26	19	45	717	879	239	1835
European Ancestry	Clearance	1	8	9	39	232	421	692
	Persistence	2	8	10	128	521	376	1025
	Total	3	16	19	167	753	797	1717

European Ancestry (Number of haplotypes= 1087)					
Haplotype rs4803221- rs368234815			Frequency in Clearance (Number of haplotypes= 310)	Frequency in Persistence (Number of haplotypes= 777)	OR (95% CI, P value)
G-ΔG Haplotype	G	ΔG	0.53	0.66	1
C-ΔG Haplotype	C	ΔG	0.47	0.34	1.7 (1.3-2.29, 3.6x 10 ⁻⁵)
Haplotype rs368234815- rs8099917					
ΔG-G Haplotype	ΔG	G	0.51	0.63	1
ΔG-T Haplotype	ΔG	T	0.49	0.37	1.6 (1.3-2.16, 1.76x 10 ⁻⁴)
African Ancestry (Number of haplotypes= 2333)					
Haplotype rs4803221- rs368234815			Frequency in Clearance (Number of haplotypes= 319)	Frequency in Persistence (Number of haplotypes= 1994)	OR (95% CI, P value)
G-ΔG Haplotype	G	ΔG	0.29	0.30	1
C-ΔG Haplotype	C	ΔG	0.71	0.71	1.02 (0.78-1.32, 0.88)
Haplotype rs368234815- rs8099917					
ΔG-G Haplotype	ΔG	G	0.08	0.10	1
ΔG-T Haplotype	ΔG	T	0.92	0.90	1.25 (0.81-1.9, 0.29)


IFNL4 Gene



Effect associated on Hepatitis C virus infection



Panel of sequenced individuals



Fine Mapping of Genome Wide Association Signal in *IFNL* locus

Analysis of sequenced panel of discordant and concordant individuals
(n=19 European Ancestry,
45 African Ancestry)

Variants with alternative allele count differences ≥ 5

Conditional analysis in independent imputed dataset
(n=1717 European Ancestry,
1835 African Ancestry)

Variants with significant effect after conditioning



Identification of potential causal variants in all individuals
(n=1739 European Ancestry,
n= 1869 African Ancestry)

Identification of credible set of potentially causal variants

Variants with evidence of independent effect in both approaches


Haplotype analysis.
Identification of a core haplotype

99% Credible set of variants




C

Block 1 (11 kb)



Block 1 (5 kb)



Physical Distance: 11.3 kb
LD Map Type: r-square

